Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program

The Defense Health Agency is soliciting price quotes from pharmaceutical manufacturers for four newly approved drugs scheduled for review by the Department of Defense Pharmacy and Therapeutics Committee in February 2026: Aqvesme (Metabolic Agents-Miscellaneous), Forzinity (Metabolic Agents-Miscellaneous), Omlonti (Glaucoma Agents), and Voyxact (Nephrology Agents). The solicitation seeks quotes for both Uniform Formulary Blanket Purchase Agreements (UF BPA) and Uniform Formulary Additional Discount Program (UF ADP) agreements to support the Military Health System's pharmacy benefits program. Qualified manufacturers must have an existing Federal Supply Schedule contract and must submit detailed pricing information including National Drug Code (NDC) pricing for various package sizes under multiple pricing scenarios, such as non-Federal Average Manufacturer Price (non-FAMP) and Wholesale Acquisition Cost (WAC) discounts. The government will evaluate pharmaceutical agents based on relative clinical effectiveness, relative cost-effectiveness, and potential formulary placement classifications including Basic Core Formulary, Extended Core Formulary, and non-formulary designations. Critical deadlines include a pre-quotation teleconference on January 14, 2026, clinical question responses due by a date specified in the RFQ, and all quotation responses due by January 26, 2026, with the P&T Committee meeting scheduled for February 4-5, 2026.

This solicitation contains no set-aside designations and is open to all qualified manufacturers with existing Federal Supply Schedule contracts. The government has not disclosed specific award values or budget ranges; however, award amounts will depend on the P&T Committee's formulary placement recommendations and the pricing submitted by manufacturers. Manufacturers may submit pricing for up to ten National Drug Codes per drug, with options to request additional tables if needed, and all quotes must include fully executed signature pages. The procurement supports the Military Health System's integrated pharmacy benefits program serving active duty personnel, retirees, and family members across multiple pharmacy venues including Military Treatment Facilities, mail-order pharmacy, and TRICARE retail network locations. Performance of awarded agreements will span these military and TRICARE pharmacy venues nationwide, with the Defense Health Agency serving as the contracting entity and the DHA Director serving as the final approval authority for formulary placement recommendations.